Peptide Library

Human study PLS-00178

Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4.

Case report · Not reported participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4.primary · Archives of ophthalmology (Chicago, Ill. : 1960) · 2010-05-01 · PMID 20457990 · DOI

Design and participants

Design
Case report
Population
Patients with chronic nonhealing neurotrophic corneal epithelial defects (number and characteristics not stated in the record)
Conditions
Neurotrophic keratopathy, Chronic nonhealing corneal epithelial defects
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • Thymosin beta 4 (intervention) · thymosin-beta-4 · Thymosin beta 4, indexed with the MeSH topic Ophthalmic Solutions · Topical ophthalmic (eye drops, inferred from MeSH topic Ophthalmic Solutions) · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Healing of corneal epithelial defect

unclear outcome · patient-important · Not stated in the record

  • No results reported.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • abstract only: The record holds only the title and PubMed indexing. There is no abstract or full text, so methods, sample size and results cannot be appraised.
  • no control group: The study is indexed as Case Reports and describes treatment with no comparison group, so no comparative effect can be estimated.
  • small or imprecise: Case reports or series typically involve very few patients. The number treated is not stated in the record.
  • selection bias: The patients were chronic nonhealing cases selected for treatment, and the selection process is not described.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: PMID 20457990, title (title: treatment with thymosin beta 4; MeSH Ophthalmic Solutions) · extracted by AI (automated, not verified by a person)
  • design: PMID 20457990, title (PubMed publication type Case Reports and title) · extracted by AI (automated, not verified by a person)
  • limitations: PMID 20457990, title (record lacks abstract; publication type Case Reports) · extracted by AI (automated, not verified by a person)
  • outcomes: PMID 20457990, title (title: treatment of nonhealing epithelial defects) · extracted by AI (automated, not verified by a person)
  • population: PMID 20457990, title (title: chronic nonhealing neurotrophic corneal epithelial defects) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).